Wilson-Cook Medical recalled 60 units of Nasal Jejunal Feeding Tube NJFT-10 on December 15, 2025. The tubes were packaged without the necessary nasal transfer tube component. This defect poses a high hazard risk for patients requiring feeding assistance.
Nasal feeding tube packaged without the nasal transfer tube component.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Wilson-Cook Medical Inc. or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the Nasal Jejunal Feeding Tube, REF: NJFT-10. Lot codes affected include W4904253, W4886945, and W4880750, with a UDI of 10827002223018. The tubes were distributed internationally to Australia.
The nasal feeding tube lacks the nasal transfer tube component, which is critical for proper function. Without this component, patients may face serious risks associated with improper feeding.
No specific incidents or injuries have been reported related to this recall. The potential for injury remains high due to the critical nature of the device.
Stop using the Nasal Jejunal Feeding Tube immediately. Follow the recall instructions provided by Wilson-Cook Medical. Contact your healthcare provider or Wilson-Cook Medical for further instructions.
For more information, contact Wilson-Cook Medical Inc. via email regarding the recall. Additional details are available at the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.